Autopsy report · NCT03711162

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

“The benefit-risk profile no longer supports continuing the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 4 months before it stopped.
• 525 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Lakefront Biotherapeutics NV

Sponsor type

Industry

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

GLPG1690; Placebo

Participants

525

Sites

132

Countries

Australia, Belgium, Brazil, Chile, Czechia, Denmark, Germany, Greece, Japan, Peru, Spain, Taiwan and more

Trials that died the same way

• A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
  “Study terminated due to an unfavorable risk-benefit analysis” (78% match in meaning)
• Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
  “Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.” (75% match in meaning)
• Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
  “Trial terminated based on benefit-risk profile assessment” (75% match in meaning)
• A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
  “Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study” (69% match in meaning)
• An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
  “The study was terminated early due to sponsor decision unrelated to safety or efficacy findings” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.